The first oral Gonadotropin-Releasing Hormone (GnRH) Antagonist combined with add-back therapy in Europe, licensed specifically for Uterine Fibroids (UF)1
Balances efficacy and safety2-4
Significantly reduces heavy menstrual bleeding2
>70% of women respond to Ryeqo2,5
Significantly reduces pain associated with UF2,6
Significant improvement in quality of life7
Inhibits ovulation and provides adequate contraception after one month of treatment1*
Established safety profile2,4
Bone health preserved during 104 weeks’ treatment1
...FOR THE LIFE SHE WANTS.
*Ryeqo inhibits ovulation in women taking the recommended dose and provides adequate contraception. Ovulation will return rapidly after discontinuing treatment.